Apotex Bags First Biosimilar Neulasta, Plans To Undercut Amgen In Canada By 25%
Executive Summary
Apotex is hoping to sell its biosimilar version of Amgen’s Neulasta at a 25% discount in Canada after gaining approval there in what seems to be a world first. Might the Canadian OK help unblock the path to approval in the US and the EU?
You may also be interested in...
EMA ‘Yes’ For Pegfilgrastim Biosimilars Spells End For Neulasta’s EU Stronghold
Approval of the first pegfilgrastim biosimilars in the EU would mark the start of a period of accelerated sales declines for Amgen's Neulasta but the outlook for the blockbuster bio-originator is not necessarily bleak.
EMA ‘Yes’ For Pegfilgrastim Biosimilars Spells End For Neulasta’s EU Stronghold
Approval of the first pegfilgrastim biosimilars in the EU would mark the start of a period of accelerated sales declines for Amgen's Neulasta but the outlook for the blockbuster bio-originator is not necessarily bleak.
EU First For Pegfilgrastim Biosimilars? EMA Decides This Week
Two biosimilar versions of Amgen’s blockbuster drug, Neulasta, are up for an opinion from the European Medicines Agency this week on whether they should be approved in the EU. Coherus is the sponsor of one of the products.